Compositions and methods for protecting against airborne pathogens and irritants
AssigneeApplied Biological Laboratories, Inc.
InventorNazlie LATEFI
Life of this patent
Estimating the term…
Abstract
The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses.
Claims32
A pharmaceutical composition for preventing or treating respiratory infection comprising:
- (i) soluble ICAM-1 or an ICAM-1 inhibitor;
- (ii) sialic acid (e.g., sialyllactose);
- (iii) lysozyme;
- and
- (iv) lactoferrin;
- and
- a pharmaceutically acceptable carrier.
A method of preventing or treating respiratory infection comprising:
- administering to the nasal or oral mucosa of a human a composition comprising:
- soluble ICAM-1 or an ICAM-1 inhibitor;
- (ii) sialic acid (e.g., siallyllactose);
- (iii) lysozyme;
- (iv) lactoferrin;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating respiratory infection from human rhinovirus (HRV) comprising:
- (i) about 0.00000001% to about 10% by weight soluble ICAM-1;
- (ii) about 0.00000001% to about 10% by weight lysozyme;
- and
- (iii) about 0.00000001% to about 10% by weight lactoferrin;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating respiratory infection from human influenza virus comprising:
- (i) about 0.0000005% to about 10% by weight of said sialic acid (e.g., sialyllactose);
- (ii) about 0.000005% to about 10% by weight of said lysozyme;
- (iii) about 0.00000025% to about 10% by weight of said lactoferrin;
- and
- (iv) 0% (or from about 0.01%) to about 10% by weight of a neuraminidase inhibitor;
- and
- a pharmaceutically acceptable carrier.
A composition for application to the nasal or oral mucosa, comprising one or more antiviral and/or antimicrobial agents dispersed in a liquid carrier comprising from about 60-90% (v/v) water and from about 10-40% (or from 20-30%) (v/v) of a polyol, wherein said composition is capable of being sprayed onto the mucosa, and is adapted to remain on the mucosa for at least 5 minutes (or at least 10 minutes, or at least 15 minutes, or at least 20 minutes, or at least 25 minutes, or at least 30 minutes) following application without substantially irritating or drying the mucosa.
Dependencies are inferred from the claim text.